Access to anti-retroviral drugs, female in Congo

Congo: Access to anti-retroviral drugs, female was 33.0% in 2024. ◆ Volatile

Latest (2024)
33.0%
Change on year
up 10.0%
World rank
133rd
of 141 countries
All-time high
33.0%
in 2024
All-time low
0.0%
in 2000
Years of data
25
2000–2024

Access to anti-retroviral drugs, female in Congo, 2000–2024

01020302000201220242000: 0 %2001: 0 %2002: 0 %2003: 0 %2004: 0 %2005: 3 %2006: 3 %2007: 4 %2008: 9 %2009: 12 %2010: 14 %2011: 19 %2012: 18 %2013: 21 %2014: 20 %2015: 21 %2016: 23 %2017: 24 %2018: 25 %2019: 25 %2020: 25 %2021: 25 %2022: 28 %2023: 30 %2024: 33 %

Source: UNAIDS estimates. Measured in %.

Analysis

Congo recorded 33.0% for access to anti-retroviral drugs, female in 2024. That is the highest value across all 25 years on record.

The figure is up 10.0% on the previous year and up 65.0% over ten years.

Over the whole period, access to anti-retroviral drugs, female in Congo peaked at 33.0% in 2024 and was at its lowest, 0.0%, in 2000.

That places Congo 133rd out of 141 countries with data for 2024, putting it in the bottom quarter.

The series is highly variable year to year, so single readings are best treated with caution.

Access to anti-retroviral drugs, female in Congo, year by year

Annual values for Access to anti-retroviral drugs, female (%) in Congo, 2000 to 2024.
Year % Change
2000 0.0%
2001 0.0%
2002 0.0%
2003 0.0%
2004 0.0%
2005 3.0%
2006 3.0% +0.0%
2007 4.0% +33.3%
2008 9.0% +125.0%
2009 12.0% +33.3%
2010 14.0% +16.7%
2011 19.0% +35.7%
2012 18.0% -5.3%
2013 21.0% +16.7%
2014 20.0% -4.8%
2015 21.0% +5.0%
2016 23.0% +9.5%
2017 24.0% +4.3%
2018 25.0% +4.2%
2019 25.0% +0.0%
2020 25.0% +0.0%
2021 25.0% +0.0%
2022 28.0% +12.0%
2023 30.0% +7.1%
2024 33.0% +10.0%

Averages by decade

DecadeAverage LowestHighest Years
2000s 3.1% 0.0% 12.0% 10
2010s 21.0% 14.0% 25.0% 10
2020s 28.2% 25.0% 33.0% 5

Countries ranked near Congo

  1. 130 Indonesia 36.0% compare
  2. 130 Mongolia 36.0% compare
  3. 132 Yemen 34.0% compare
  4. 133 Bangladesh 33.0% compare
  5. 133 Tunisia 33.0% compare
  6. 136 Pakistan 24.0% compare

See the full ranking of 160 places →

More gender data for Congo

All data for Congo →

Frequently asked questions

What is access to anti-retroviral drugs, female in Congo?
Access to anti-retroviral drugs, female in Congo was 33.0% in 2024, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, female recorded in Congo?
The highest recorded value was 33.0% in 2024.
What is the lowest access to anti-retroviral drugs, female recorded in Congo?
The lowest recorded value was 0.0% in 2000.
How does Congo rank for access to anti-retroviral drugs, female?
Congo ranks 133rd out of 141 countries with data for 2024.
Is access to anti-retroviral drugs, female rising or falling in Congo?
Over the last ten years it is up 65.0%. The long-run trend across the full record is volatile.
Where does this Congo data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, female (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, female in Congo. Statizoid, drawing on UNAIDS estimates. Retrieved 05 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/congo-rep/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/congo-rep/">Access to anti-retroviral drugs, female in Congo</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, female (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,925 data points, 2000–2024
Last refreshed

The percentage of adult females living with HIV who are receiving antiretroviral therapy.